Skip to content

Aprea Therapeutics Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco

BOSTON, MA., and STOCKHOLM, SWEDEN, January 5, 2017 – Aprea Therapeutics, a
privately held, clinical stage biopharmaceutical company developing novel anticancer
therapies targeting the tumor suppressor protein p53, today announced that Christian S.
Schade, President & Chief Executive Officer, is scheduled to present a company update
and overview at the 35th Annual J.P. Morgan Healthcare Conference at 7:30a.m. PT on
Wednesday, January 11, 2017 at the Westin St. Francis Hotel in San Francisco, CA.
About Aprea Therapeutics AB
Aprea Therapeutics AB is a Boston, Massachusetts- and Stockholm, Sweden-based
biopharmaceutical company focused on the discovery and development of novel
anticancer compounds reactivating the tumor suppressor protein, p53. The Company’s
lead program, APR-246, a first-in-class small molecule drug candidate, is in Phase II
clinical development in ovarian cancer patients, and additional clinical studies with APR-
246 in other cancer indications are planned. In March 2016, Aprea completed a EUR 46
million Series B financing with an international syndicate co-led by Versant Ventures and
5AM Ventures, with additional participation by Sectoral Asset Management, HealthCap,
acting as local lead investor, and existing investor, Karolinska Development. For more
information, please visit
About p53 and APR-246
The p53 tumor suppressor gene is the most frequently mutated gene in human cancer,
occurring in approximately 50% of all human tumors. These mutations are often
associated with resistance to anticancer drugs and poor overall survival, representing a
major unmet medical need in the treatment of cancer.
APR-246 has been shown to reactivate mutant p53 protein – by reconverting mutant p53
into wild-type p53 conformation and function – and thereby induce programmed cell
death in human cancer cells. APR- 246 has demonstrated compelling pre-clinical
antitumor activity in a wide variety of solid and hematological (blood) tumors, including
ovarian cancer, small cell lung cancer, esophageal cancer and AML (acute myeloid
leukemia), among others. Additionally, strong synergy has been seen with both
traditional anticancer agents, such as chemotherapy, as well as newer mechanismbased
anticancer drugs and immuno-oncology checkpoint inhibitors. In addition to preclinical
testing, Phase I clinical studies with APR-246 have been completed,
demonstrating a favorable safety profile and both biological and clinical responses in
hematological malignancies and solid tumors with mutations in the p53 gene. The
Company has commenced a Phase II study on ovarian cancer and is expecting to
initiate additional clinical studies of APR-246 in other cancer indications.
Corporate Contacts:
Christian S. Schade
President and Chief Executive Officer
Gregory A. Korbel, Ph.D.
Vice President of Business Development

Source: Aprea aprea-jpm-presentation-2017-pr_final